Key Highlights

  • Cash position of $65.1 million at 30 September 2026, with no borrowings, sufficient to fund operations well into 2028
  • Net operating cash outflow of $10.4 million in Q1 FY27, up from $8.3 million in Q4 FY26, driven by R&D and staff costs
  • Research and development expenditure rose to $5.7 million in Q1 FY27, compared with $4.6 million in Q4 FY26
  • $3.528 million paid to major Shareholder Cochlear Ltd (ASX:COH) during the quarter to advance next-generation Minder device R&D

A Pioneering Device Company Burning Cash With Purpose

Melbourne-based Epiminder Limited (ASX:EPI) is one of the more unusual propositions on the ASX — a pre-revenue medical device company backed by a $125 million IPO war chest, working to transform how clinicians manage drug-resistant epilepsy. Its first quarterly Cash Flow report for FY27 shows the company continuing to spend at pace, but with a treasury position that leaves it in a position of relative comfort.

The company ended Q1 FY27 with $65.1 million in cash and no borrowings, after recording a net operating cash outflow of $10.4 million for the three months to 30 September 2026. That compares with an outflow of $8.3 million in Q4 FY26 and $5.7 million in Q3 FY26, a trajectory that reflects a deliberate ramp-up in activity rather than cost creep.

Where the Money Is Going

The single largest expense category was research and development, which consumed $5.7 million in the quarter — up sharply from $4.6 million in Q4 FY26 and $3.8 million in Q3 FY26. Staff costs, which came to $3.8 million, were elevated in part due to FY26 performance bonuses paid during the period. Administration and corporate costs added a further $1.6 million, while interest income of $0.5 million provided a partial offset.

Embedded within the R&D figure is a $3.528 million payment to Cochlear Ltd (ASX:COH), Epiminder's largest shareholder. These funds are directed at developing the next-generation Minder device, with Epiminder retaining management control over the research activities. This arrangement reflects the deep strategic link between the two companies — Cochlear was a founding collaborator in bringing the original Minder system to market.

The Minder Device and DETECT Study

Epiminder's lead product, the Minder system, holds the distinction of being the first FDA-authorised implantable continuous EEG monitoring device. It is designed to give neurologists high-quality electroencephalography data over months or years, enabling remote assessment and better-informed treatment decisions for patients living with drug-resistant epilepsy — a population with limited management Options under the current standard of care.

The company is currently running the DETECT study, its pivotal clinical program, which represents the main driver of near-term expenditure. From inception through to 30 September 2026, Epiminder has deployed approximately $3.8 million against the $25 million originally earmarked for the DETECT program in its prospectus. By contrast, R&D expenditure against the next-generation device program has reached $15.7 million of a $32 million budget — indicating that the bulk of Capital deployment has so far been weighted toward device development rather than the clinical program.

Total proceeds utilised since the IPO, including offer costs and convertible note repayments, stand at approximately $68.8 million out of $133.9 million available, leaving roughly $65.1 million on hand.

Sector Context

Epiminder operates at the intersection of neurology, implantable devices and digital health — a segment attracting growing attention as healthcare systems seek scalable tools to manage the roughly 30% of epilepsy patients whose seizures cannot be adequately controlled with medication. Continuous EEG monitoring at scale has historically been impractical outside hospital settings; implantable solutions like Minder aim to move that capability into everyday life.

The ASX has a thin bench of pure-play neurotech names, making Epiminder a relatively distinctive listing. That distinction comes with the inherent risks of a pre-revenue company: clinical trial execution risk, regulatory pathway risk and the concentration of outcomes around a single product platform.

Risks

Investors watching Epiminder need to keep several factors front of mind. The company remains wholly pre-revenue, meaning the entire Investment case rests on successful execution of the DETECT study and commercialisation of Minder. Any delays to recruitment, adverse clinical findings or shifts in FDA guidance could materially affect timelines and cash requirements.

The accelerating quarterly Burn Rate — from $5.7 million in Q3 FY26 to $10.4 million in Q1 FY27 — warrants monitoring, even though current cash reserves remain adequate under the company's stated funding runway. Staff costs rising sharply in a single quarter, even when explained by Bonus timing, is a line item that will draw scrutiny if it persists.

The Cochlear relationship, while strategically valuable, introduces a degree of dependency. Should that arrangement change, Epiminder's next-generation device pathway could be affected.

What to Watch Next

The company's Annual General Meeting on 30 October 2026 was flagged as the venue for an operating update, which may provide clearer guidance on DETECT study progress and enrolment milestones. Beyond that, the next Appendix 4C — covering the December quarter — will be closely watched to see whether the R&D spend plateau or continues upward as DETECT activity intensifies.

Progress payments against the $25 million DETECT budget are a particularly useful signal of programme momentum. At $3.8 million spent after more than a year of activity, the clinical programme appears to be in relatively early stages, and any update on enrolment numbers will be valuable context.